Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June
Nanexa announces that the results from the recently completed Phase I-study with NEX-22 have been approved as a Late Breaking Abstract at the prestigious ADA Congress (American Diabetes Association) held in Chicago June 20-23.
The abstract presents results from the Phase I-study with NEX-22, developed in collaboration with the renowned CRO Profil in Germany, specializing in diabetes research.
NEX-22 is Nanexa´s PharmaShell based one-month depot of the GLP-1 substance liraglutide, intended for the treatment of type 2 diabetes. Liraglutide is currently administrated as a daily injection. NEX-22 is expected to simplify treatment and thereby increase adherence.
"This is a recognition of our interesting data with NEX-22," says David Westberg, CEO of Nanexa. "We look forward to both scientific discussions and the opportunity to meet companies within the industry. This is a welcome contribution to our business development and strengthens our position in diabetes research and treatment."
The abstract has been selected to be part of the poster presentation during the congress and will also be published on the journal Diabetes® website in June.
